

1Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington; 2Department of Community Medicine, Gastrointestinal and Liver Disease Research Center, University of Tehran, Tehran, Iran; 3Minima University, Jimma, Ethiopia; 4Aswan Faculty of Medicine, Aswan, Egypt; 5Department of Neurology, Cairo University, Cairo, Egypt; 6GlaxoSmithKline, Philadelphia, Pennsylvania; 7Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; 8Health Services Management Research Center, Institute for Futures Studies in Health, Karman University of Medical Sciences, Tehran, Iran; 9University of Rochester, Cary, North Carolina; 10Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; 11Bielefeld University, Bielefeld, Germany; 12Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; 13University of Melbourne, Melbourne, Australia; 14University of Sydney, Sydney, Australia; 15Ministry of Health, Al Khuwayt, Oman; 16University of Oxford, Oxford, United Kingdom; 17Kingdom of Saudi Arabia Ministry of Health, Riyadh, Saudi Arabia; 18Division of Physical Therapy, Department of Rehabilitation Sciences, Jordan University of Science and Technology, Irbid, Jordan; 19Ministry of Health, Jeddah, Saudi Arabia; 20Charité Universitätsmedizin, Berlin, Germany; 21Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates; 22King Saud University, Riyadh, Saudi Arabia; 23Universidad de Cartagena, Cartagena de Indias, Colombia; 24Ministry of Public Health, Beirut, Lebanon; 25Department of Health Policy and Administration, College of Public Health, University of the Philippines, Manila, Philippines; 26Department of Medical Emergency, School of Paramedic, Qom University of Medical Sciences, Qom, Iran; 27South Asian Public Health Forum, Islamabad, Pakistan; 28Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan; 29Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; 30School of Health Sciences, University of Management and Technology, Lahore, Pakistan; 31Public Health Agency of Canada, Toronto, Canada; 32Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 33College of Public Health and Tropical Medicine, Jazan, Saudi Arabia; 34Madawalabu University, Bale Goba, Ethiopia; 35University of Sao Paolo, Sao Paulo, Brazil; 36Mekelle University, Mekelle, Ethiopia; 37Medical Center, Aga Khan University, Karachi, Pakistan; 38University of Iowa Hospitals and Clinics, Iowa City, Iowa; 39Al Shifa Trust Eye Hospital, Rawapindi, Pakistan; 40Walden University, Minneapolis, Minnesota; 41International Institute for Population Sciences, Mumbai, India; 42Arba Minch University, Arba Minch, Ethiopia; 43London School of Hygiene and Tropical Medicine, London, United Kingdom; 44University of Louisville, Louisville, Kentucky; 45Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts; 46Institute for Health Policy, Boston, Massachusetts; 47Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran; 48Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; 49Bielefeld University, Bielefeld, Germany; 50Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; 51Melbourne Health, Parkville, Australia; 52College of Medicine, University of Hail, Hail, Saudi Arabia; 53Haramaya University, Dire Dawa, Ethiopia; 54Kersa Health and Demographic Surveillance System, Harar, Ethiopia; 55Department of Microbiology, Saint James School of Medicine, Anguilla, British West Indies; 56Department of Epidemiology and Biostatistics, Saint James School of Medicine, Anguilla, British West Indies; 57West Virginia Bureau for Public Health, Charleston, West Virginia; 58Kilte Awlaelo Health and Demographic Surveillance System, Ethiopia; 59African Gulf University, Manama, Bahrain; 60Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; 61Department of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; 62Department of Epidemiology, Salah Azaiez Institute, Tunis, Tunisia; 63Qatar University, Doha, Qatar; 64Department of Public Health, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 65University of Aberdeen, Aberdeen, United Kingdom; 66Addis Ababa University, Debre Zeit, Ethiopia; 67Wageningen University, Wageningen, Netherlands; 68Department of Ophthalmology, 

*Address correspondence to Ali H. Mokdad, Institute for Health Metrics and Evaluation, 2301 5th Avenue, Suite 600, Seattle, WA 98121. E-mail: mokdad@u.washington.edu

1319
over the past 20 years, the incidence of childhood diarrhea mortality due to DD has declined significantly in children. Vaccinations, and death.2 For those who survive these illnesses, repeated infections by enteric pathogens in the early years of life can lead to Talal enteric dysfunction, growthfaltering, impaired cognitive development, reduced immune response to infection and vaccinations, and death.3 Although a wide spectrum of bacterial, viral, and parasitic pathogens are responsible for infectious diarrhea worldwide, their etiologic contribution may vary depending on the geographic location of the study, study durations, or the population sampled.3 In addition, variations in the reported frequency of diarrhea may reflect the diagnostic tools used rather than the actual incidence of each pathogen.4 Furthermore, coinfections are common and more than one pathogen may be implicated in cases of diarrhea.

INTRODUCTION

Diarrheal diseases (DD) are a major cause of childhood mortality globally, resulting in approximately 550,000 deaths among children under 5 years of age each year.1 Although mortality due to DD has declined significantly in children over the past 20 years, the incidence of childhood diarrhea in low-income countries (LICs) has not fallen appreciably.1 For those who survive these illnesses, repeated infections by enteric pathogens in the early years of life can lead to serious lifelong health consequences such as environmental enteric dysfunction, growth faltering, impaired cognitive development, reduced immune response to infection and vaccinations, and death.3 Although a wide spectrum of bacterial, viral, and parasitic pathogens are responsible for infectious diarrhea worldwide, their etiologic contribution may vary depending on the geographic location of the study, study durations, or the population sampled.3 In addition, variations in the reported frequency of diarrhea may reflect the diagnostic tools used rather than the actual incidence of each pathogen.4 Furthermore, coinfections are common and more than one pathogen may be implicated in cases of diarrhea. The Eastern Mediterranean Region (EMR) is home to more than 500 million people, representing a diverse group of 22 countries, including Arab states in north Africa, Gulf nations, and countries in west Asia. EMR countries have diverse historical backgrounds, political and social contexts, and fiscal and cultural influences on their health-care systems. The region has wide variation in per capita gross national product, ranging from a high of $134,420 in Qatar to a low of $2,000 in Afghanistan.5 Such wide variation has a major influence on overall health spending and results in substantial health inequities both within and across countries.
Furthermore, the region has witnessed long years of political instability and conflicts, including the recent Arab Spring uprising and conflicts in countries such as Syria and Yemen.

Many countries in the EMR achieved important successes in the 1970s and 1980s with the support of the United Nations International Children’s Emergency Fund and the World Health Organization (WHO) through the National Control of Diarrheal Diseases Project. For example, Egypt’s program, which spanned from 1981 to 1991, was credited with significantly improving diarrheal case management. However, over the last two decades, the momentum has slowed. As of January 2016, rotavirus vaccines have been introduced through national immunization programs in only three (Djibouti, Republic of Sudan, and Yemen) of 11 Gavi-eligible countries in the region. The perceived lack of urgency relative to the major political and economic challenges facing the region has contributed to the current low level of awareness regarding the remaining burden of diarrhea. To date, there remains a lack of adequate research to address these diseases in many EMR countries.

Our objective in this report is to establish the size of the burden, distribution of pathogens, and risk factors for diarrhea in children and adults in the EMR for 1990 through 2013.

**MATERIALS AND METHODS**

**Study region.** The EMR countries were grouped according to per capita gross national income (GNI) into LICs (Islamic Republic of Afghanistan [Afghanistan], Djibouti, Somalia, Republic of Yemen [Yemen]); middle-income countries (MICs) (Arab Republic of Egypt [Egypt], Islamic Republic of Iran [Iran], Iraq, Jordan, Lebanon, Libya, Morocco, Pakistan, Palestine, Sudan, Syrian Arab Republic [Syria], Tunisia); and high-income countries (HICs) (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates [UAE]). We defined LICs as those having a per capita GNI of $1,045 or less, MICs as those with a per capita GNI between $1,046 and $12,735, and HICs as countries with per capita GNI of $12,736 or greater.

**Global burden of disease.** The Global Burden of Disease Study 2013 (GBD 2013) is a systematic, comprehensive effort to quantify health loss from 306 causes of diseases and injuries, 240 causes of death, and 79 risk factors by sex and age groups between 1990 and 2013 for 188 countries. GBD 2013’s estimation process, including that for DD, has been described in detail elsewhere. The burden of DD was measured in disability-adjusted life years (DALYs), the sum of years of life lost due to premature death (YLLs) and years lived with disability (YLDs). The methods used to calculate each of these are summarized below.

**Mortality.** Cause-specific mortality estimates, including those for DD, were modeled using a Bayesian ensemble modeling process. Diarrhea mortality data included vital registration and verbal autopsy sources. The modeling process estimated the mortality rate due to diarrhea for both genders from 1990 to 2013 for all age groups in every country, and in subnational areas of some countries. Covariates, such as improved water and sanitation sources, malnutrition, and population density were considered. The ensemble model approach allowed for a suite of models, weighted by out-of-sample predictive validity, to inform the final estimates.

**Morbidity.** As with mortality, morbidity is modeled at every year, gender, age, and geographic location in the GBD study. We used DisMod-MR 2.0, a Bayesian meta-regression mixed effects model, to calculate morbidity. DisMod-MR was originally developed for GBD 2010 to address statistical challenges in estimating nonfatal health outcomes and synthesizing sparse and heterogeneous epidemiological data. It uses nonlinear mixed effects models that include country- and study-level covariates to generate priors for increasingly detailed geographic regions in an analytic cascade. Prevalence, incidence, recovery, and death are related in a series of ordinary differential equations within DisMod-MR. Basically, it is a mathematical modeling technique that takes data collected from different sources, corrects for inconsistencies, and fills in gaps when data are incomplete, ultimately producing estimates of disease burden by age, sex, and country. A full description of DisMod-MR is available elsewhere.

Diarrhea prevalence and incidence data from a systematic literature review and population-representative surveys informed the meta-analytic model and estimates.

**Etiologies.** Diarrhea cases and deaths were attributed to pathogens using a counterfactual approach. A systematic literature review on the proportion of diarrhea cases that test positive for a set of pathogens is used in the DisMod-MR framework to estimate the age, sex, year, and geographic distribution of diarrheal pathogens. The population-attributable fraction (PAF) is used to parse the fraction of diarrhea cases and deaths due to each pathogen. The PAF is calculated as

\[
PAF = \frac{\text{proportion} \times (1 - 1/[\text{odds ratio},])}
\]

Where “proportion” is the proportion of cases positive for a pathogen and “odds ratio” (OR) is the odds of diarrhea given pathogen detection. The ORs were derived from the Global Enteric Multicenter Study (GEMS), a multisite case-control study of moderate-to-severe diarrhea in children under 5 years of age, using a mixed effects conditional logistic regression model. With the exception of Pakistan, where the ORs were calculated from a model including only the Pakistan GEMS site, the ORs were calculated from a model that included all GEMS sites.

*Vibrio cholerae* and *Clostridium difficile* were estimated separately from the other pathogens in GBD. Cholera cases were estimated using data from previous studies compared with WHO case notification data to estimate underreporting. Cholera deaths were estimated using case fatality data in DisMod-MR. Since *C. difficile* is frequently associated with hospital and health-care utilization, hospital incidence data were modeled in DisMod-MR 2.0.

**Risk factors.** We also assessed diarrheal DALYs, YLLs, and YLDs attributable to childhood stunting (below -2 standard deviations of the median height of a reference population), suboptimal breastfeeding (nonexclusive breastfeeding and discontinued breastfeeding), vitamin A deficiency, zinc deficiency, and water, sanitation, and hygiene (WASH).

**Data analysis.** The average decrease in deaths, DALYs, YLLs, and YLDs was calculated by subtracting the mean estimate in 1990 from the mean estimate in 2013, divided by 23 years. All reported rates are per 100,000 persons and are not age standardized. Uncertainty for deaths, DALYs, and
attributable fractions in GBD were derived from 1,000 draws of the variables used to estimate these outcomes. For example, the ORs, pathogen prevalence among diarrhea cases, and mortality rates are from normal or log-normal distributions and were combined at the draw level to estimate pathogen-specific diarrhea mortality. The 95% uncertainty intervals (UIs) then are the 2.5 and 97.5 percentiles of these estimates. This analysis was conducted using Stata/SE 13.1 (StataCorp LP, College Station, TX) and maps were generated using the ggplot2\textsuperscript{18} package in R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Deaths. There were 128,024 (95% UI = 88,729–172,361) diarrhea-related deaths in the EMR in 2013, with an overall rate of 21 diarrheal deaths per 100,000 persons (95% UI = 14–28) (Table 1). The majority of these deaths occurred among children under 5 years of age (68.9%) (88,172, 95% UI = 52,794–129,711) and adults over 70 years of age (11.9%) (15,278, 95% UI = 9,491–22,518). There were no consistent differences in diarrhea deaths per 100,000 between males and females (Supplemental Figure 1). There were some exceptions to the general pattern of children under 5 years of age bearing the greatest burden. In Djibouti, in the year 2000, diarrhea deaths per 100,000 were greater among those over 70 years of age (680, 95% UI = 394–1,088) than among those under 5 years of age (187, 95% UI = 84–332). In neighboring Somalia, death rates were also higher for individuals over 70 years of age versus individuals under 5 years of age at each time point.

Graphs of diarrhea deaths per 100,000 demonstrated a steady decrease from 1990 to 2013, with the most notable declines among children under 5 years of age and individuals ≥70 years of age (Figure 1). For all ages, diarrhea death rates decreased by an average of 2.39% deaths per 100,000 per year during this period. For those under 5, 5–14, 15–49, 50–69, and over 70 years of age, the average decrease in the diarrheal death rate was 11.17%, 0.39%, 0.17%, 0.78%, and 4.96% per 100,000 per year, respectively. The 2013 diarrheal-death rates were stratified by country and per capita GNI (Figure 2). Diarrhea deaths per 100,000 children under 5 years of age ranged from one (95% UI = 0–1), in Bahrain and Oman (HICs), to 471 (95% UI = 245–763), in Somalia (a LIC) (Supplemental Table 1). Among MICs, Pakistan (225, 95% UI = 144–315) and Sudan (120, 95% UI = 61–189) had diarrhea death rates in excess of their economic peers. Overall, diarrhea mortality appeared to be related to per capita GNI rather than geographical location.

**Years of life lost due to premature mortality.** Nearly 9 million (8,935,214, 95% UI = 5,865,116–12,571,874) YLLs were attributable to diarrhea in the EMR in 2013. Children under 5 years of age bore the majority (84.5%) of this burden (7,553,654, 95% UI = 4,517,051–11,112,683), and had a rate of 10,361 (95% UI = 6,196–15,242) YLLs per 100,000. Children under 5 years of age in Bahrain (37, 95% UI = 34–88), Oman (59, 95% UI = 31–108) and Qatar (95, 95% UI = 53–167) experienced the lowest rates of YLLs per 100,000 in the region. On the other hand, children in Somalia (40,238, 95% UI = 20,975–65,112) and Afghanistan (20,675, 95% UI = 11,160–31,515), two countries with the longest history of ongoing civil wars in the region, experienced the highest rates.

**Years lived with disability.** Diarrhea was responsible for a total of 1,002,096 (95% UI = 673,662–1,392,552) YLDs in 2013 in the region, with children under 5 years of age contributing more than half of this burden (586,935, 95% UI = 391,944–820,782). The rate of YLDs per 100,000 among children under 5 years of age was 805 (95% UI = 538–1,126) and ranged from 177 (95% UI = 106–263) in Djibouti to 974 (95% UI = 662–1,357) in Afghanistan.

**Disability-adjusted life years.** Nearly 10 million DALYs were attributable to diarrhea (9,937,310, 95% UI = 6,802,456–13,650,080), with an overall rate of 1,610 (95% UI = 1,102–2,212) DALYs per 100,000 in the EMR in 2013 (Table 2). The majority of DALYs were borne by those under 5 years of age (81.9%) (8,140,589, 95% UI = 5,082,597–11,726,801) and those 15–49 years of age (7.4%) (737,925, 95% UI = 498,093–1,058,052). There were no consistent differences in diarrhea-associated DALYs between males and females.

The average decrease in the number of DALYs over this time period in the region as a whole was 568,035 per year, with the majority of this decrease among those under 5 and 5–14 years of age (543,789 and 23,734 DALYs per year, respectively). The pattern for diarrhea DALYs among those under 5 years of age closely followed that for diarrheal deaths. DALY rates ranged from 739 (95% UI = 520–989) in Syria to 40,869 (95% UI = 21,540–65,823) in Somalia.

In each country, diarrhea DALYs decreased over time and children under 5 years of age consistently contributed the majority of diarrhea DALYs (Supplemental Figure 2).

**Etiologies.** The proportion of deaths attributable to specific etiologies in 2013, excluding cholera and C. difficile, are presented in Figure 3. Generally, rotavirus infection was the largest contributor to the diarrheal burden of disease. However, Shigella was the greatest contributor to diarrheal deaths and DALYs in Sudan. When also considering cholera and C. difficile, the total proportion of attributable deaths was greater than 100% (more than one attributable

---

**Table 1**

Diarrheal disease-associated deaths in the EMR, 2013

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Sex</th>
<th>Deaths (UI)</th>
<th>Rate* (UI)</th>
<th>% of total†</th>
</tr>
</thead>
<tbody>
<tr>
<td>All ages</td>
<td>Male</td>
<td>64,690 (38,893–95,066)</td>
<td>20 (12–30)</td>
<td>3.29</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>63,334 (38,706–92,897)</td>
<td>21 (13–31)</td>
<td>3.88</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>128,024 (88,729–172,361)</td>
<td>21 (14–28)</td>
<td>3.56</td>
</tr>
<tr>
<td>&lt;5</td>
<td>Male</td>
<td>44,346 (20,941–72,951)</td>
<td>118 (56–195)</td>
<td>11.19</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>43,826 (21,668–71,417)</td>
<td>124 (61–201)</td>
<td>12.70</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>88,172 (52,794–129,711)</td>
<td>212 (72–178)</td>
<td>11.90</td>
</tr>
<tr>
<td>5–14</td>
<td>Male</td>
<td>2,484 (1.113–4,690)</td>
<td>4 (2–7)</td>
<td>4.68</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>3,105 (1.467–5,590)</td>
<td>5 (2–9)</td>
<td>7.17</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>5,589 (3.175–9,011)</td>
<td>4 (2–7)</td>
<td>5.80</td>
</tr>
<tr>
<td>15–49</td>
<td>Male</td>
<td>4,634 (2,381–7,942)</td>
<td>3 (1–5)</td>
<td>1.14</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>4,878 (2,537–8,189)</td>
<td>3 (2–5)</td>
<td>1.81</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>9,512 (5,755–14,736)</td>
<td>3 (2–4)</td>
<td>4.41</td>
</tr>
<tr>
<td>50–69</td>
<td>Male</td>
<td>5,091 (2.584–8,884)</td>
<td>15 (8–27)</td>
<td>0.97</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>4,383 (2.105–7,859)</td>
<td>13 (6–24)</td>
<td>1.13</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>9,474 (4.857–15,012)</td>
<td>24 (8–23)</td>
<td>1.04</td>
</tr>
<tr>
<td>70+</td>
<td>Male</td>
<td>8,136 (4,253–13,493)</td>
<td>106 (55–175)</td>
<td>1.38</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>7,142 (3,800–12,096)</td>
<td>83 (44–140)</td>
<td>1.22</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>15,278 (7,941–22,518)</td>
<td>94 (58–138)</td>
<td>1.30</td>
</tr>
</tbody>
</table>

*EMR = Eastern Mediterranean Region; UI = uncertainty interval.
†Rate is per 100,000.
‡Percent of total deaths in the EMR for the specified age group and sex.
pathogen per diarrheal episode) for Jordan, Palestine, Syria, Bahrain, and Oman (Supplemental Figure 3). These same five countries also had a relatively large proportion of diarrheal deaths attributed to cholera in 2013 and an increasing cholera burden in the recent years (Supplemental Figure 4). Graphs of the relative proportions of known etiologies leading to diarrheal DALYs for children under 5 years of age are provided in Supplemental Figure 5.

Risk factors. In 2013, the two risk factors that contributed to the greatest number of diarrhea-attributable deaths (Supplemental Figure 6) and DALYs (Supplemental Figure 7) among those under 5 years of age were WASH and suboptimal breastfeeding. Rates of suboptimal breastfeeding-related deaths ranged from zero (0, 95% UI = 0–1) in Bahrain and Oman to 232 (95% UI = 105–405) in Somalia. The same pattern was seen with rates of WASH-related deaths, where Bahrain and Oman had a rate of one (95% UI = 0–1) and Somalia’s rate was 457 (95% UI = 238–734). WASH-related deaths and DALYs were somewhat greater in LICs, and the burden due to
suboptimal breastfeeding was generally greater in HICs (Supplemental Figures 8 and 9).

**DISCUSSION**

We reported the most comprehensive assessment of DD burden and the contributions of specific pathogens and risk factors in the EMR to date. In 2013, the estimated diarrhea-associated deaths and DALYs were more than 125,000 and nearly 10 million, respectively. We also found substantial variation within the region, with LICs and MICs experiencing social unrest bearing the vast majority of diarrheal burden.

Our estimates are comparable with others from recent publications. A systematic literature review published in 2008 estimated diarrhea deaths among those under 5 years of age in 13 EMR countries (Bahrain, Cyprus, Iran, Jordan, Kuwait, Lebanon, Libya, Oman, Qatar, Saudi Arabia, Syria, Tunisia, and the UAE) to be 12,000 (UI = 10,000–14,000), and in nine other EMR countries (Afghanistan, Djibouti, Egypt, Iraq, Morocco, Pakistan, Somalia, Sudan, and Yemen) to be 221,000 (UI = 190,000–250,000).19 Our estimated number of DD-associated deaths in this age group, which combines these two subregions, was similar. In addition, although we did not follow the same grouping of countries in our

![Figure 3](image-url)  
**Figure 3.** The proportion of diarrheal deaths due to known pathogens,* among children under 5 years of age in the Eastern Mediterranean Region, 2013 (*excluding cholera and *Clostridium dificile*).
Our study has several limitations and strengths. First, while our modeling process seeks to make use of all available data, the number of relevant publications in the region is limited and unbalanced between countries. However, our hierarchical modeling approach allows us to “borrow” strength across time and geography to generate the best possible estimates. Second, since we only account for the acute phase of diarrhea in our YLD estimates, the resulting DALYs severely underestimate diarrhea-associated morbidity. In GBD 2016, we expect to include long-term sequelae such as stunting and cognitive impairment, which will better estimate the true burden of disease. Third, the reported distribution of diarrhea etiologies was based on traditional laboratory detection techniques, which may be less sensitive and specific than molecular methods. For this reason, our future GBD estimates will incorporate a GEMS reanalysis based on standardized quantitative polymerase chain reaction data for all pathogens. Despite these limitations, this analysis also has several strengths. GBD methodology ensures internal consistency so that morbidity and mortality cannot be simultaneously ascribed to competing causes and allows for comparability between countries and across regions.

CONCLUSIONS

Although there were substantial improvements in DD-related morbidity and mortality, the health inequities revealed in our data show that more action is needed to reduce the burden of diarrhea in the EMR, especially in lower-income countries and countries experiencing political and social unrest. A coordinated approach that involves prevention and treatment is needed to address the multiple causes of DD. Regional health systems need to be strengthened to achieve the widespread availability and use of oral rehydration salts, improved rates of breastfeeding, improved nutrition, better sanitation and hygiene, and increased coverage of measles immunization. Due to the high relevance of rotavirus infections in EMR, there is also an urgent need to roll out rotavirus vaccine in the region through government immunization programs that would ensure access for the children who are most in need. In addition, regional governments should begin deliberation to integrate Shigella, enterotoxigenic Escherichia coli, and other diarrheal vaccines that are currently in preclinical and clinical trials into their expanded programs on immunization as soon as they are approved and licensed.


